QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Celadon Pharmaceuticals Share Price, News & Analysis (LON:CEL)

GBX 105
0.00 (0.00%)
(As of 11/29/2023 ET)
Compare
Today's Range
100
▼
110
50-Day Range
81.34
▼
138
52-Week Range
N/A
Volume
160,627 shs
Average Volume
59,865 shs
Market Capitalization
£65.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 222.50
Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlines

CEL stock logo

About Celadon Pharmaceuticals Stock (LON:CEL)

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

CEL Stock Price History

CEL Stock News Headlines

November 16, 2023 | lse.co.uk
Celadon shares rise on supply contract worth up to GBP26 million
October 13, 2023 | marketwatch.com
Celadon Pharmaceuticals to Raise GBP1 Mln via Discounted Placing, Subscription
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 1, 2023 | finance.yahoo.com
Celadon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)
September 28, 2023 | lse.co.uk
Celadon Pharmaceuticals interim loss narrows; optimistic for future
September 5, 2023 | lse.co.uk
Celadon shares rise on second UK contract win for cannabis product
September 5, 2023 | marketwatch.com
Celadon Pharmaceuticals Enters New Contract Worth Up to GBP1.2 Mln in Revenue
August 22, 2023 | finance.yahoo.com
Owning 61% in Celadon Pharmaceuticals Plc (LON:CEL) means that insiders are heavily invested in the company's future
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
August 1, 2023 | ca.finance.yahoo.com
CEL.L - Celadon Pharmaceuticals Plc
August 1, 2023 | lse.co.uk
Celadon receives approval for 5,000 patient clinical cannabis trial
June 9, 2023 | finance.yahoo.com
Investors’ Chronicle: Oxford Metrics, N Brown, Celadon Pharmaceuticals
June 5, 2023 | lse.co.uk
Celadon Pharmaceuticals loss widens; confident amid three-year deal
May 30, 2023 | lse.co.uk
Celadon secures GBP7 million credit facility as product demand grows
May 30, 2023 | marketwatch.com
Celadon Pharmaceuticals Shares Rise on New GBP7 Mln Line of Credit
May 24, 2023 | lse.co.uk
Celadon signs commercial cannabis supply agreement with UK firm
May 24, 2023 | lse.co.uk
CORRECT: Celadon signs commercial cannabis supply agreement in UK
April 20, 2023 | finance.yahoo.com
C15 Solutions Anticipates Substantial Growth in European Cannabis Market Through Innovative Tech Platform
March 15, 2023 | finance.yahoo.com
James Short Celadon Pharmaceuticals Plc's (LON:CEL) CEO is the most bullish insider, and their stock value gained 162%last week
March 14, 2023 | thetimes.co.uk
Fresh permit for cannabis lifts Celadon
March 14, 2023 | marketwatch.com
Celadon Pharmaceuticals Shares Jump as Sale of Pharmaceutical Cannabis Product Granted
January 16, 2023 | thetimes.co.uk
Celadon wins right to cultivate and make medicinal cannabis oil
January 16, 2023 | markets.businessinsider.com
Celadon Pharma's Midlands UK Facility Gets GMP Registration By MHRA; Stock Up
January 16, 2023 | marketwatch.com
Celadon Pharmaceuticals Shares Rise After UK Quality Standard Registration
November 2, 2022 | marketwatch.com
Cast PVC Film Market 2022 Research Report Recent Developments, Size, Share, Growth Strategies, Segment by Type, Region and Future Forecast 2028
October 1, 2022 | lse.co.uk
EARNINGS UPDATES: Crestchic raises outlook on record year-to-date
September 9, 2022 | finance.yahoo.com
SPOT APPOINTS SENIOR VICE PRESIDENT FOR HUMAN RESOURCES
See More Headlines
Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:CEL
CUSIP
N/A
CIK
N/A
Web
www.celadonpharma.co.uk
Phone
44 20 3150 0252
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 222.50
High Stock Price Target
GBX 235
Low Stock Price Target
GBX 210
Potential Upside/Downside
+111.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-7,960,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-122.33%
Return on Assets
-35.60%

Debt

Debt-to-Equity Ratio
153.26
Current Ratio
1.86
Quick Ratio
6.97

Sales & Book Value

Annual Sales
£11,258.00
Price / Sales
5,826.39
Cash Flow
GBX 34.40 per share
Price / Cash Flow
3.05
Book Value
GBX 5 per share
Price / Book
21.00

Miscellaneous

Outstanding Shares
62,470,000
Free Float
N/A
Market Cap
£65.59 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. James Gareth Short (Age 55)
    CEO & Executive Director
    Comp: $246.15k
  • Mr. Jonathan Paul Turner (Age 45)
    CFO & Director
  • Ms. Kerin Williams (Age 53)
    Company Secretary

Key Competitors

View All Competitors














CEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Celadon Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CEL shares.
View CEL analyst ratings or view top-rated stocks.

What is Celadon Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1 year price objectives for Celadon Pharmaceuticals' shares. Their CEL share price targets range from GBX 210 to GBX 235. On average, they anticipate the company's share price to reach GBX 222.50 in the next year. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for CEL or view top-rated stocks among Wall Street analysts.

How have CEL shares performed in 2023?

Celadon Pharmaceuticals' stock was trading at GBX 50.50 on January 1st, 2023. Since then, CEL shares have increased by 107.9% and is now trading at GBX 105.
View the best growth stocks for 2023 here.

How do I buy shares of Celadon Pharmaceuticals?

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:CEL) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -